title: Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.
abstract: The Comprehensive Geriatric Assessment (CGA) represents the future of the geriatric oncology to reduce toxicities and treatment-related hospitalization in the elderly. Most patients receiving docetaxel for metastatic castration-resistant prostate cancer are in their seventies or older. We explored the efficacy of the CGA in predicting chemotherapy feasibility and response to docetaxel in a cohort of 24 patients aged at least 70. This was an observational, prospective study involving 24 patients who were 70 years of age or older and about to start chemotherapy with docetaxel for metastatic castration-resistant prostate cancer; we performed a CGA including five domains and divided our patients into 'healthy' and 'frail'; the relations between general condition and (i) early chemotherapy discontinuation and (ii) response to docetaxel were explored. We found a statistically significant relationship between frailty assessed by CGA and early docetaxel discontinuation; we also found an association between frailty and response to chemotherapy, but this did not reach statistical significance. A geriatric assessment before starting chemotherapy may help clinicians to recognize frail patients, and hence to reduce toxicities and early treatment discontinuation. Further analyses are required to simplify the CGA tools and to facilitate its incorporation into routine clinical practice.
authors: aDivision of Medical Oncology, Department of Uro-Gynaecological Oncology 'Istituto Nazionale Tumori' 'Fondazione G. Pascale'-IRCCS bUnit of Epidemiology, 'Istituto Nazionale Tumori' 'Fondazione G. Pascale' - IRCCS cDivision of Medical Oncology, 'San Gennaro dei Poveri' Hospital, Naples dDepartment of Onco-Ematology and Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto eDivision of Medical Oncology, 'San Giuseppe Moscati' Hospital, Avellino fDivision of Medical Oncology, 'Gaetano Rummo' Hospital, Benevento gDepartment of Medical Oncology, National Cancer Institute, Aviano, Italy.
authors: Chiara
authors: C
authors: Della Pepa
authors: Carla
authors: C
authors: Cavaliere
authors: Sabrina
authors: S
authors: Rossetti
authors: Marilena
authors: M
authors: Di Napoli
authors: Sabrina C
authors: SC
authors: Cecere
authors: Anna
authors: A
authors: Crispo
authors: Carlo
authors: C
authors: De Sangro
authors: Emanuela
authors: E
authors: Rossi
authors: Dino
authors: D
authors: Turitto
authors: Domenico
authors: D
authors: Germano
authors: Gelsomina
authors: G
authors: Iovane
authors: Massimiliano
authors: M
authors: Berretta
authors: Carmine
authors: C
authors: D'Aniello
authors: Salvatore
authors: S
authors: Pisconti
authors: Luigi
authors: L
authors: Maiorino
authors: Bruno
authors: B
authors: Daniele
authors: Cesare
authors: C
authors: Gridelli
authors: Sandro
authors: S
authors: Pignata
authors: Gaetano
authors: G
authors: Facchini
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077143:Docetaxel; D015577:Geriatric Assessment / Q000379:methods*; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D011446:Prospective Studies; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel